DRG-101 is also known as DeltaRex-G. So it is a tumor targeted retro vector encoding CCNG1 inhibitor gene, and CCNG1 is basically a non-canonical cyclin. So our poster is basically about utilizing DeltaRex-G in patients with advanced pancreatic cancer, advanced sarcomas and breast cancer, to see which patients would respond favorably to DeltaRex-G. We test them for levels of CCNG1 expression. Previously we reported, that all sarcoma tumors have enhanced CCNG1 expression...
DRG-101 is also known as DeltaRex-G. So it is a tumor targeted retro vector encoding CCNG1 inhibitor gene, and CCNG1 is basically a non-canonical cyclin. So our poster is basically about utilizing DeltaRex-G in patients with advanced pancreatic cancer, advanced sarcomas and breast cancer, to see which patients would respond favorably to DeltaRex-G. We test them for levels of CCNG1 expression. Previously we reported, that all sarcoma tumors have enhanced CCNG1 expression. So in this report, we have our expanded our analysis to 137 patients with other cancer types. And our results show that 100% tumors basically have enhanced CCNG1 expression. So this tells us that DeltaRex-G has potential of platform therapy upon which other FDA approved cancer drugs can be added. And DeltaRex-G is promising therapy for, um, basically even advanced pancreatic cancer, sarcomas and breast cancer. We have patients with prolonged survival who have been on DeltaRex-G as monotherapy. So it looks great. And DeltaRex-G is not sponsored by any pharma companies or insurance companies. It is basically provided by Aveni Foundation, which is a charity that is that runs on generous donations of benefactors. So, uh, we do encourage donations to Aveni Foundation.